# 4 Days Left: What an NSAID That Doesn’t Hurt Your Stomach Could Mean for 30 Million Americans | Sen-Jam Pharmaceutical

- Canonical URL: https://wefunder.com/feed/291744
- Entity ID: wefunder:feed_item:291744
- Published at: 2026-03-31 15:12:33 UTC
- Updated at: 2026-04-01 09:21:18 UTC

## Author
Jim Iversen

## Subject
Sen-Jam Pharmaceutical

## Content
Dear Sen-Jam Investors & Community,Saturday I gave you the plan. Sunday I showed you the platform proof. Monday I took you inside the blood analysis and Atlas. Today I want to talk about the single largest commercial opportunity in our portfolio — and the FDA meeting that opens the door to it.I want to talk about stomachs.The Problem Everyone Knows AboutIf you’ve ever taken ibuprofen, naproxen, or aspirin, someone has told you to take it with food. Your doctor has warned you about stomach issues. The label says it right on the bottle. And if you’ve taken NSAIDs regularly — for arthritis, for chronic pain, for inflammation — you may have experienced it firsthand: the upset stomach, the nausea, the worry about ulcers.This isn’t a minor inconvenience. It’s a public health crisis hiding in plain sight.Over 30 million Americans take NSAIDs regularly. Over 100,000 are hospitalized every year for NSAID-induced gastrointestinal complications — bleeding, ulcers, perforation. For patients with inflammatory bowel disease, Crohn’s disease, or ulcerative colitis, NSAIDs aren’t just risky — they’re contraindicated. The medical consensus for decades has been clear: if you have GI disease, you cannot take NSAIDs. Period.That means millions of patients with both arthritis and GI disease — a condition called enteropathic arthritis — are locked out of the most effective and affordable class of anti-inflammatory drugs available. Their alternative? Injectable biologics costing $20,000 to $50,000+ per year that suppress the immune system and still only treat one component of their disease.We believe we’ve solved this problem. And we have three independent lines of evidence to back it up.Three Lines of Evidence. One Conclusion.Evidence 1: Our own clinical trial.In the SJP-002X Phase 2 trial, we gave 150 patients indomethacin — a drug that gastroenterologists use as the benchmark for GI toxicity. It’s the NSAID they point to when they say “this is why NSAIDs are dangerous for your stomach.” We combined it with ketotifen, a mast cell stabilizer, and administered it for 14 days.The result: zero serious adverse events. Adverse event rates indistinguishable from placebo. We gave 150 people one of the harshest NSAIDs on the market, and their GI profile looked like they were taking a sugar pill.Evidence 2: An independent scientific review.In 2025, Dijkgraaf and colleagues published an independent systematic review (manuscript under review) — that analyzed the published scientific literature and confirmed: ketotifen eliminates indomethacin-induced gastrointestinal injury. And it does it through a mechanism that’s completely different from the antacids and PPIs that people currently use. It’s not acid suppression. It’s mast cell stabilization — preventing the inflammatory damage at its source, in the gut wall itself.Evidence 3: A second clinical trial with a different combination.Our SJP-001 Phase I/II trial tested a completely different NSAID + co-agent pairing — naproxen + fexofenadine — in 49 subjects across multiple dosing periods in a controlled crossover design. The GI tolerability was confirmed. This tells us the gastroprotection isn’t a quirk of one specific drug pair. It’s a property of the architecture itself: mast cell stabilizer + NSAID = protected gut.Three sources. Two clinical trials. One independent review. All pointing to the same conclusion: we can make NSAIDs safe for the stomach.What This Is WorthLet me put this in commercial terms.The inflammatory bowel disease market is $25–30 billion globally. It’s dominated by biologics — drugs like Humira and Entyvio — that cost tens of thousands of dollars per year, require injection or infusion, suppress the immune system, and in many cases only treat one component of a multi-component disease. Our oral combination costs less than $2 to manufacture, treats both the arthritis and the GI disease simultaneously, and doesn’t suppress the immune system.But the opportunity is much bigger than enteropathic arthritis.If a mast cell stabilizer protects the gut in IBD patients — the most GI-vulnerable population on earth — then it protects the gut in everyone. Think about what that means for the 30+ million Americans who take NSAIDs regularly. Think about what it means for the companies that make ibuprofen, naproxen, and diclofenac. Think about what an OTC label could look like that says “clinically shown to protect the stomach” instead of “may cause stomach bleeding.”That’s not a drug. That’s a franchise transformation. And there are major pharmaceutical companies with NSAID portfolios worth billions who would pay a premium for this technology.The FDA Meeting That Opens the DoorWe hold a granted U.S. patent — US 10,765,630 — covering methods of treating enteropathic arthritis with our NSAID + mast cell stabilizer combination. The patent is granted. The claims are in place. The evidence is in hand.What’s next is FDA engagement. And that’s exactly what your investment is building toward: a Pre-IND meeting with the agency.The Pre-IND meeting is where we present the three lines of GI-protection evidence, propose a clinical trial design, and ask the FDA: “Do you agree that this data supports studying our combination in patients with GI disease — the population that has been locked out of NSAIDs for 40 years?”If the FDA says yes — and our evidence package is designed to make that answer as clear as possible — it’s the regulatory starting gun for the largest commercial opportunity in our portfolio. It opens the path to a Phase 2 clinical trial in enteropathic arthritis, which opens the path to NDA approval, which opens the path to the broader gastroprotection market.And here’s the part that ties back to Monday’s update: when we walk into that FDA meeting, the blood analysis data comes with us. Not just clinical outcomes. Objective molecular evidence showing exactly how the combination protects the gut at the pathway level. That’s a fundamentally different conversation with the agency than “our trial showed acceptable safety.” It’s “here’s the molecular mechanism, confirmed by our data, validated by an independent review, and reproduced across two different drug combinations.”This Is What You’re Investing InI’ve given you seven investor updates across the past month and a half. The first three showed you the data from SJP-001, SJP-002X, and SJP-005. The fourth showed you how that data strengthened three additional patents. Saturday gave you the plan. Sunday showed you the platform foundation. Monday showed you the blood analysis that powers Atlas.Today I’m showing you where the science meets the market. An NSAID that doesn’t hurt your stomach isn’t an incremental improvement. It’s a category shift. It’s the answer to a problem that 30 million Americans live with every time they reach for a bottle of ibuprofen. And the evidence says we’ve found it.Every dollar invested this week moves this forward. The blood analysis powers the molecular evidence. The regulatory strategy opens the FDA conversation. The Pre-IND meeting puts the evidence in front of the people who decide whether this becomes a product. And the patents protect it all.This is what your investment is building. A platform that could change how the world thinks about NSAIDs.Invest Now on Wefunder → wefunder.com/senjamReg CF maximum: $5M | Campaign closes April 3, 2026Before investing, I’m happy to answer your questions. You can schedule a one-on-one call with me HERE.Let’s do this...JimForward-Looking Statements: This communication contains forward-looking statements that involve risks and uncertainties. SJP-001, SJP-002X, SJP-004, and all Sen-Jam pipeline assets are investigational drug candidates and have not been approved by the FDA or any regulatory authority. Clinical and preclinical trial results are not guarantees of future outcomes. Valuations and market estimates represent management’s current assessment based on available data and third-party analyses and are not guarantees of future value. The gastroprotection mechanism described herein is based on clinical observations and independent literature review; regulatory outcomes from FDA engagement are not guaranteed. References to addressable market sizes reflect publicly available industry estimates and are not projections of Sen-Jam revenue. This does not constitute an offer to sell or solicitation of an offer to buy securities. Review offering documents on Wefunder for complete risk disclosures before making an investment decision.